中国医师进修杂志
中國醫師進脩雜誌
중국의사진수잡지
CHINESE JOURNAL OF POSTGRADUATES OF MEDICINE
2011年
19期
32-33
,共2页
刘小莲%朱万寿%刘志%黄世俭%李胜华
劉小蓮%硃萬壽%劉誌%黃世儉%李勝華
류소련%주만수%류지%황세검%리성화
白血病,髓样%白细胞介素2%T淋巴细胞亚群%药物疗法,联合
白血病,髓樣%白細胞介素2%T淋巴細胞亞群%藥物療法,聯閤
백혈병,수양%백세포개소2%T림파세포아군%약물요법,연합
Leukemia,myeloid%Interleukin-2%T-lymphocyte subsets%Drug therapy,combination
目的 探讨急性髓系白血病患者化疗后应用白细胞介素-2(IL2)治疗对细胞免疫功能的影响及其临床意义.方法 将54例急性髓系白血病患者按随机数字表法分为IL-2联合化疗组(治疗组,28例)和单纯化疗组(对照组,26例),治疗组于化疗后每天加用IL-2 40万U静脉滴注,连用2周,检测两组治疗前后T淋巴细胞亚群的变化.结果 治疗组治疗后CD3(0.6026±0.2275)、CD4(0.4972±0.1224)、CD56(0.3016±0.1053)明显高于治疗前(分别为0.3926±0.2010、0.2264±0.1190、0.1729±0.1226)及对照组治疗后(分别为0.4352±0.1930、0.2738±0.1362、0.1937±0.1268),差异均有统计学意义(P<0.05).结论 IL-2联合化疗能明显提高急性髓系白血病患者T淋巴细胞亚群的水平,对提高机体的免疫功能有积极的作用.
目的 探討急性髓繫白血病患者化療後應用白細胞介素-2(IL2)治療對細胞免疫功能的影響及其臨床意義.方法 將54例急性髓繫白血病患者按隨機數字錶法分為IL-2聯閤化療組(治療組,28例)和單純化療組(對照組,26例),治療組于化療後每天加用IL-2 40萬U靜脈滴註,連用2週,檢測兩組治療前後T淋巴細胞亞群的變化.結果 治療組治療後CD3(0.6026±0.2275)、CD4(0.4972±0.1224)、CD56(0.3016±0.1053)明顯高于治療前(分彆為0.3926±0.2010、0.2264±0.1190、0.1729±0.1226)及對照組治療後(分彆為0.4352±0.1930、0.2738±0.1362、0.1937±0.1268),差異均有統計學意義(P<0.05).結論 IL-2聯閤化療能明顯提高急性髓繫白血病患者T淋巴細胞亞群的水平,對提高機體的免疫功能有積極的作用.
목적 탐토급성수계백혈병환자화료후응용백세포개소-2(IL2)치료대세포면역공능적영향급기림상의의.방법 장54례급성수계백혈병환자안수궤수자표법분위IL-2연합화료조(치료조,28례)화단순화료조(대조조,26례),치료조우화료후매천가용IL-2 40만U정맥적주,련용2주,검측량조치료전후T림파세포아군적변화.결과 치료조치료후CD3(0.6026±0.2275)、CD4(0.4972±0.1224)、CD56(0.3016±0.1053)명현고우치료전(분별위0.3926±0.2010、0.2264±0.1190、0.1729±0.1226)급대조조치료후(분별위0.4352±0.1930、0.2738±0.1362、0.1937±0.1268),차이균유통계학의의(P<0.05).결론 IL-2연합화료능명현제고급성수계백혈병환자T림파세포아군적수평,대제고궤체적면역공능유적겁적작용.
Objective To investigate the influence and the clinical significance of interleukin-2 (IL-2) on T lymphocyte subgroup after chemotherapy in acute myeloid leukemia patients. Methods Fiftyfour acute myeloid leukemia patients were divided into treatment group (chemotherapy combined with IL-2,28 cases) and control group (pure chemotherapy,26 cases) by radom digits table. In treatment group, IL-2400 000 U was dripped after chemotherapy for 14 days. Then the T lymphocyte subgroup change before and after treatment was examined. Results After 14 days' treatment, the levels of CD3 (0.6026±0.2275 ),CD4(0.4972±0.1224),CD56(0.3016±0.1053 ) in treatment group were significantly higher than those before treatment(0.3926±0.2010,0.2264±0.1190,0.1729±0.1226) and in control group (0.4352±0.1930,0.2738±0.1362,0.1937±0.1268)(P< 0.05). Conclusion IL-2 treatment can obviously raise the levels of T lymphocyte subgroup and can raise the immunologic function.
